Richard Glickman

Richard Glickman

Vorsitzender bei ENGENE HOLDINGS INC.

Vermögen: 649 733 $ am 30.04.2024

65 Jahre
Health Technology
Finance
Commercial Services

Profil

Richard M.
Glickman
founded Aurinia Pharmaceuticals, Inc. in 1993, where he worked as Chairman & Chief Executive Officer from 2013 to 2019 and Aspreva Pharmaceuticals Corp.
in 2001, where he worked as Chairman & Chief Executive Officer from 2001 to 2006.
Dr. Glickman also founded Probtec Corp., Nventa Biopharmaceuticals Corp., where he worked as Chief Executive Officer, Stressgen Biotechnologies Corp., where he worked as Chief Executive Officer, Ontario Molecular Diagnostics, where he worked as Director, Aurinia Pharmaceuticals, Inc., where he worked as Chief Executive Officer, and Aurinia Pharma Corp., where he worked as Chairman & Chief Executive Officer from 2017 to 2019.
Dr. Glickman also currently works at ESSA Pharma, Inc., as Chairman from 2010, enGene Holdings, Inc., as Chairman from 2024, MedGenesis Therapeutix, Inc., as Director, enGene, Inc., as Director from 2011, Eupraxia Pharmaceuticals, Inc., as Director from 2021, Vida Pharmaceuticals Pvt Ltd., as Director, Eurpraxia Pharmaceuticals, Inc., as Director, and Lumira Capital Investment Management, Inc., as Venture Partner.
Dr. Glickman also formerly worked at Vigil Health Solutions, Inc., as Chairman, LifeSciences British Columbia, as Chairman, BC Biotech, as Chairman, Correvio Pharma Corp., as Lead Independent Director, Canadian Genetic Disease Network, as Director, Vancouver Aquarium, as Director, viDA Therapeutics, Inc., as Director, Innovate BC, as Member, and Kearny Venture Partners, as Venture Partner.
Dr. Glickman received his undergraduate degree from McGill University.

Bekannte Unternehmensbeteiligungen

UnternehmenDatumAnzahl der AktienBewertungDatum der Bewertung
28.05.2024 24 675 ( 0,06% ) 363 216 $ 30.04.2024
24.04.2024 43 240 ( 0,10% ) 264 629 $ 30.04.2024
13.05.2024 7 680 ( 0,02% ) 21 888 $ 30.04.2024

Aktive Positionen von Richard Glickman

UnternehmenPositionBeginn
ESSA PHARMA INC. Vorsitzender 01.10.2010
EUPRAXIA PHARMACEUTICALS INC. Direktor/Vorstandsmitglied 09.03.2021
ENGENE HOLDINGS INC. Vorsitzender 15.05.2024
Private Equity Investor -
Vida Pharmaceuticals Pvt Ltd. Direktor/Vorstandsmitglied -
Direktor/Vorstandsmitglied -
Direktor/Vorstandsmitglied 23.09.2011
Alle aktiven Positionen von Richard Glickman

Ehemalige bekannte Positionen von Richard Glickman

UnternehmenPositionEnde
AURINIA PHARMACEUTICALS INC. Vorstandsvorsitzender 29.04.2019
Vorstandsvorsitzender 01.01.2019
░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░ ░░░░░░░ ░░░░░░░ ░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ -
░░░░░░░ ░░░░░ ░░░░░░░░ -
Sehen Sie sich die Erfahrung von Richard Glickman im Detail an

Ausbildung von Richard Glickman

McGill University Undergraduate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Richard Glickman im Detail an

Beziehungen

100 +

Beziehungen ersten Grades

25

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Börsennotierte Unternehmen4
EUPRAXIA PHARMACEUTICALS INC.

Health Technology

ESSA PHARMA INC.

Health Technology

AURINIA PHARMACEUTICALS INC.

Health Technology

ENGENE HOLDINGS INC.

Health Technology

Private Unternehmen20

Health Technology

Health Technology

Health Technology

Electronic Technology

Health Technology

Health Technology

Finance

Stressgen Biotechnologies Corp. /Bioreagents Business/

Health Technology

Commercial Services

Health Technology

Canadian Genetic Disease Network

Finance

Commercial Services

Miscellaneous

Health Technology

Ontario Molecular Diagnostics

Probtec Corp.

Aurinia Pharmaceuticals, Inc. /Old/

Health Technology

Retail Trade

Vida Pharmaceuticals Pvt Ltd.

Sehen Sie sich die Unternehmensverbindungen an
  1. Börse
  2. Insiders
  3. Richard Glickman
-40 % Zeitlich begrenztes Angebot: Unsere Abonnements führen Sie zu den besten Investitionen von morgen.
PROFITIEREN SIE JETZT